EK. Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1␣-Kv1.5 O 2-sensing pathway at the intersection of pulmonary hypertension and cancer. Am J Physiol Heart Circ Physiol 294: H570 -H578, 2008. First published December 14, 2007 doi:10.1152/ajpheart.01324.2007.-Pulmonary arterial hypertension (PAH) is a lethal syndrome characterized by vascular obstruction and right ventricular failure. Although the fundamental cause remains elusive, many predisposing and disease-modifying abnormalities occur, including endothelial injury/dysfunction, bone morphogenetic protein receptor-2 gene mutations, decreased expression of the O 2-sensitive K ϩ channel (Kv1.5), transcription factor activation [hypoxia-inducible factor-1␣ (HIF-1␣) and nuclear factor-activating T cells], de novo expression of survivin, and increased expression/activity of both serotonin transporters and platelet-derived growth factor receptors. Together, these abnormalities create a cancerlike, proliferative, apoptosis-resistant phenotype in pulmonary artery smooth muscle cells (PASMCs). A possible unifying mechanism for PAH comes from studies of fawn-hooded rats, which manifest spontaneous PAH and impaired O 2 sensing. PASMC mitochondria normally produce reactive O 2 species (ROS) in proportion to PO2. Superoxide dismutase 2 (SOD2) converts intramitochondrial superoxide to diffusible H 2O2, which serves as a redox-signaling molecule, regulating pulmonary vascular tone and structure through effects on Kv1.5 and transcription factors. O 2 sensing is mediated by this mitochondria-ROS-HIF-1␣-Kv1.5 pathway. In PAH and cancer, mitochondrial metabolism and redox signaling are reversibly disordered, creating a pseudohypoxic redox state characterized by normoxic decreases in ROS, a shift from oxidative to glycolytic metabolism and HIF-1␣ activation. Three newly recognized mitochondrial abnormalities disrupt the mitochondria-ROS-HIF-1␣-Kv1.5 pathway: 1) mitochondrial pyruvate dehydrogenase kinase activation, 2) SOD2 deficiency, and 3) fragmentation and/or hyperpolarization of the mitochondrial reticulum. The pyruvate dehydrogenase kinase inhibitor, dichloroacetate, corrects the mitochondrial abnormalities in experimental models of PAH and human cancer, causing a regression of both diseases. Mitochondrial abnormalities that disturb the ROS-HIF-1␣-Kv1.5 O 2-sensing pathway contribute to the pathogenesis of PAH and cancer and constitute promising therapeutic targets.hypoxia-inducible factor-1␣; nuclear factor-activating T cells; voltage-gated potassium channels; fawn-hooded rats; mitochondrial fusion; pyruvate dehydrogenase kinase; lung cancer; reactive oxygen species; mitochondrial electron transport chain PULMONARY ARTERIAL HYPERTENSION is a disease of the pulmonary vasculature, which occurs in a rare idiopathic form (sporadic-